Zoptarelin doxorubicin consists of doxorubicin linked to a small peptide agonist to the luteinizing hormone-releasing hormone (LHRH) receptor.
CAT No: R2005
CAS No:139570-93-7
Chemical Name:[2-[(2S,4S)-4-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-3,4-dihydro-1H-tetracen-2-yl]-2-oxoethyl] 5-[[(5R)-6-[[(2S)-1-[[(2S)-1-[(2S)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-carbamimidamido-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-[[(2S)-2-[[(2S)-3-hydroxy-2-[[(2S)-2-[[(2S)-3-(1H-imidazol-5-yl)-2-[[(2S)-5-oxopyrrolidine-2-carbonyl]amino]propanoyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-6-oxohexyl]amino]-5-oxopentanoate
Zoptarelin doxorubicin is a synthetic peptide-drug conjugate that combines a gonadotropin-releasing hormone (GnRH) analog with the anthracycline chemotherapeutic agent doxorubicin. As a targeted delivery construct, it leverages the specificity of peptide-mediated receptor binding to facilitate the cellular uptake of its cytotoxic payload in receptor-expressing cells. Structurally, the conjugate consists of a GnRH analog covalently linked to doxorubicin, enabling selective interaction with GnRH receptors, which are known to be overexpressed in certain tumor cell types and also present in various normal tissues. The unique architecture of this molecule makes it a valuable tool for probing receptor-mediated drug delivery, peptide conjugate design, and the mechanisms underlying targeted cytotoxicity in biochemical and pharmacological research.
Targeted drug delivery research: Zoptarelin doxorubicin is extensively utilized in studies focused on receptor-mediated drug delivery systems. By exploiting the high affinity of the GnRH analog for its cognate receptor, researchers can investigate the efficiency and selectivity of ligand-directed cytotoxic agent transport into specific cell populations. This line of research is critical for optimizing the design of peptide-drug conjugates and for understanding the parameters that govern cellular uptake, endosomal escape, and intracellular trafficking of such constructs. The conjugate serves as a model system to evaluate how peptide targeting can enhance the therapeutic index of cytotoxic agents in vitro and in vivo.
Peptide conjugate mechanism studies: The compound plays a pivotal role in elucidating the mechanistic aspects of peptide-drug conjugate action. By tracking the fate of the doxorubicin moiety following receptor binding and internalization, researchers can dissect the processes of receptor-mediated endocytosis, lysosomal release, and the subsequent induction of cellular responses such as DNA intercalation and apoptosis. These studies provide insight into the structure-activity relationships that influence conjugate stability, cleavage kinetics, and bioactivity, informing the rational design of next-generation targeted therapeutics and diagnostic agents.
Receptor expression profiling: Zoptarelin doxorubicin is a valuable probe for mapping the distribution and density of GnRH receptors across various cell lines and tissue samples. By utilizing its receptor-targeted binding properties, investigators can quantify receptor expression levels using fluorescence or cytotoxicity-based assays. Such profiling is instrumental in identifying suitable cellular models for targeted delivery research, validating receptor overexpression in disease models, and correlating receptor abundance with cellular susceptibility to peptide-drug conjugates.
Cellular uptake and trafficking assays: The conjugate is widely employed in cellular assays designed to assess the dynamics of peptide-mediated internalization and intracellular trafficking. By labeling or tracking the doxorubicin component, researchers can visualize and quantify the kinetics of conjugate entry, endosomal processing, and nuclear localization within receptor-positive cells. These studies are essential for optimizing linker chemistry, understanding off-target effects, and improving the efficiency of drug release at the intended intracellular site of action.
Cytotoxicity evaluation in model systems: Zoptarelin doxorubicin enables precise evaluation of cytotoxic effects in receptor-expressing versus receptor-negative cell lines. Through comparative viability assays, researchers can determine the degree of selectivity conferred by peptide targeting and assess the potential for minimizing nonspecific toxicity. The data generated from such studies inform the development of safer and more effective peptide-drug conjugates, supporting both basic research and preclinical development of targeted delivery strategies.
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at . We will endeavor to provide highly satisfying products and services.
Creative Peptides is a trusted CDMO partner specializing in high-quality peptide synthesis, conjugation, and manufacturing under strict cGMP compliance. With advanced technology platforms and a team of experienced scientists, we deliver tailored peptide solutions to support drug discovery, clinical development, and cosmetic innovation worldwide.
From custom peptide synthesis to complex peptide-drug conjugates, we provide flexible, end-to-end services designed to accelerate timelines and ensure regulatory excellence. Our commitment to quality, reliability, and innovation has made us a preferred partner across the pharmaceutical, biotechnology, and personal care industries.
Read More